




OCTOBER 2017

## ACQUISITIONS BOLSTER PORTFOLIO RETURNS; THIS YEAR NO DIFFERENT

An important component of our portfolio returns is the contribution from companies being acquired for a premium to the current stock price. In our small-cap strategies (Emerging Growth and AccruHealth), we typically have a few companies acquired every year. So far this year, we have had two companies announce they are being acquired: Akorn and NxStage Medical. During both 2015 and 2016, we had five portfolio companies in the small cap strategies announce they were being acquired. Since 2014, the typical premium (difference between the acquisition price and most recent stock price at the time of announcement) has been over 30%. In our large cap Total Quality Management (TQM) strategy, portfolio companies are far more likely to be an acquirer because of the company sizes. That said, TQM portfolio companies can still be acquired as evidenced by Amazon.com acquiring Whole Foods Market earlier this year.

We are investors, not speculators, so we will not buy a stock based solely on the possibility of an acquisition. That said, it may be part of our investment thesis. In addition, the attributes that cause us to invest in a company are often the same characteristics that make the company a strong acquisition candidate: a unique product offering, compelling market opportunity, good profitability (or potential profitability) and a stock price below intrinsic value.

Announced Acquisitions/Mergers of  
Small-Cap Portfolio Companies



Source: Kopp Investment Advisors

All of the portfolio companies acquired over the last four years have been acquired by a strategic buyer such as a competitor, partner or a company in an adjacent market. A strategic acquirer may pay a higher price than other potential acquirers in light of cost synergies, potential cross-selling opportunities and the purchase usually strengthens the acquirers strategic positioning.

Sometimes the financial press may report on a potential acquisition and the stock price may rise on speculation. When this happens, we may sell a portion or the entire position if we no longer view the risk-reward as favorable. For example, in our large cap TQM strategy we sold our entire Nordstrom position in August because the market was pricing in the potential for the Nordstrom family to acquire the company, which we viewed as unlikely under current market conditions. Then in October, the stock price declined after the Nordstrom family announced they were no longer considering acquiring the company this year.

**KOPP**  
**INVESTMENT ADVISORS**  
8400 Normandale  
Lake Boulevard  
Suite 1450  
Bloomington, MN  
55437

Looking forward, we believe the environment for additional merger and acquisition (M&A) activity remains favorable with strong corporate balance sheets, low interest rates and a more favorable regulatory environment. Furthermore, a lower tax rate for repatriated foreign cash could bring more cash into the U.S. and accelerate the pace of M&A. Bigger picture, we continue to have a positive outlook for the stock market. We believe stocks can grind higher

as corporate earnings growth remains strong, interest rates remain low and corporate tax rates could decline. That doesn't mean there won't be surprises and volatility, but the global economic backdrop is constructive and suggests further gains ahead.

—Dan Garofalo  
*Senior Portfolio Manager*

## CLIENT SERVICE CONTACT

**Portfolio Manager Dan Garofalo is the best contact for any client service needs you may have.**

You can reach our office at 800-333-9128. Dan can also be reached at 952-841-0457.



### DAN GAROFALO

Senior Research Analyst, Senior Portfolio Manager

Dan Garofalo joined Kopp Investment Advisors in 2013 and currently serves as Senior Portfolio Manager, Senior Research Analyst and is a member of the firm's Investment Committee. He focuses on a broad range of health care areas including medical devices, diagnostics, drug development and health care infotech and brings more than 10 years of

health care industry and investment experience in managing client portfolios. Prior to joining Kopp Investment Advisors, Dan was an equity research analyst at Piper Jaffray and also worked for a major pharmaceutical company. Dan holds an M.B.A. from the Carlson School of Management at the University of Minnesota as well as a B.A. in Business from the University of St. Thomas in St. Paul, Minnesota.

**REMINDER** Kopp Investment Advisors is an investment adviser, not a financial planner or financial consultant. We manage your account for long-term capital appreciation primarily through investing in emerging growth companies in the health care sector. Assets allocated to our AccruHealth strategy should represent the aggressive equity portion of your overall portfolio. Our investment style involves risk, including liquidity risk and market risk. This investment strategy should be used in a program of diversified investing and not as a complete investment program. You should let us know immediately in writing of any material change in your circumstances that might affect the appropriateness of our investment strategy for you or the manner in which we manage your account. We rely on you to keep us up-to-date.

© 2017 Kopp Investment Advisors, LLC.

October 17, 2017

It should not be assumed that our stock selections or investment philosophy will be profitable or will equal any past performance. Inclusion of references to individual securities is intended for illustrative purposes only. References to specific securities should not be viewed as representative of an entire portfolio, nor should the performance of any particular security be viewed as representative of the performance experienced by any other security or portfolio. Small-cap stocks involve greater risks and volatility than those of larger, more established companies. Potential for profit involves possibility of loss. This newsletter is for general information only and is not intended to provide specific advice or stock recommendations to any individual. Future investment decisions and commentary may be made under different economic, market, and industry conditions from those existing at the time these comments were prepared. Although the facts in this newsletter have been obtained from and are based on sources we believe to be reliable, we do not guarantee their accuracy, and such information is subject to change without notice. The information and opinions expressed herein are provided for informational purposes only and do not constitute a solicitation for the purchase or sale of any security or investment advisory service.